Every 10-Q that Arbutus Biopharma Corporation (ABUS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ABUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABUS filings page.
Arbutus Biopharma reported a sharp improvement in results for the six months ended June 30, 2026, driven by litigation-related license income. Total revenue was $180.1 million, up from $12.5 million a year earlier, primarily from $179.4 million of license revenue from Genevant, which includes Arbutus’ $178.4 million share of a $950.0 million noncontingent settlement payment from Moderna.
Operating expenses fell to $17.2 million from $36.7 million, reflecting prior restructuring and lower R&D. Arbutus generated net income of $164.6 million versus a $22.0 million loss in the prior-year period, although it recorded a $5.1 million net loss in the second quarter alone as settlement revenue was recognized earlier in the year. At June 30, 2026, the company held $92.6 million in cash, cash equivalents and short-term marketable securities with no debt, and also received the $178.4 million cash settlement on July 8, 2026. Management states it has sufficient resources to fund operations for at least the next 12 months while advancing hepatitis B programs, including imdusiran, which received FDA Fast Track designation, and AB‑101.
Arbutus Biopharma reported Q1 2026 revenue of $179.1M, up sharply due to recognizing $178.7M in license revenue tied to Genevant’s settlement with Moderna. This drove net income of $169.7M, compared with a loss in the prior-year quarter.
Total assets rose to $277.2M, including a $178.7M receivable from the noncontingent $950.0M Moderna settlement, while cash, cash equivalents and marketable securities were $95.2M with no debt. The company continues HBV programs for imdusiran and AB‑101 and is evaluating a potential return of capital after receiving its settlement share.
The FDA granted Fast Track designation to imdusiran for chronic hepatitis B, and Arbutus retains global rights to this RNAi candidate after ending its Qilu partnership. Litigation against Pfizer/BioNTech over LNP technology remains ongoing, and a separate contingent payment of up to $1.3B from Moderna depends on the outcome of a limited appeal.
Arbutus Biopharma (ABUS) filed its Q3 2025 report. Total revenue was $529,000, driven by $280,000 from collaborations and $249,000 of non-cash royalty revenue. Operating expenses were $9.2 million, reflecting lower R&D and G&A after earlier cost actions, and the company reported a net loss of $7.7 million, or $0.04 per share.
Year-to-date, revenue reached $13.0 million, primarily from recognizing $10.4 million of previously deferred revenue after terminating the Qilu license; net loss narrowed to $29.7 million. Cash, cash equivalents and marketable securities totaled $93.7 million as of September 30, 2025, with no debt, and management believes resources fund operations for at least the next 12 months. The company recorded $12.6 million of restructuring costs year-to-date tied to a 57% workforce reduction, exiting its headquarters, and discontinuing in-house research. As of November 11, 2025, 192,324,017 common shares were outstanding. Arbutus continues patent actions related to its LNP technology, with a U.S. trial against Moderna set for March 2026 and a September 2025 claim construction ruling in the Pfizer/BioNTech case that it considers favorable.
ABUS Q2-25 showed a sharp swing to profitability as one-time license revenue and deep cost cuts outweighed lower investment income. Total revenue rose to $10.7 m from $1.7 m a year earlier, driven mainly by recognition of $9.6 m in deferred revenue after the June termination of the Qilu partnership, which also returns worldwide rights to imdusiran. Non-cash royalty revenue from Alnylam’s ONPATTRO contributed $0.5 m.
Operating expenses fell 60% YoY to $9.3 m following a 57% workforce reduction, facility exit and R&D scale-back; Q1 restructuring charges totaled $12.4 m. As a result, operating income reached $1.5 m versus a $21.6 m loss last year, and net income reached $2.5 m ($0.01/share) versus a $19.8 m loss. For the six months, the company still posted a $22.0 m loss, but cash burn declined (operating cash outflow $29.1 m vs $33.8 m).
Cash, cash equivalents and short-term securities were $98.1 m at 30-Jun-25 (down from $122.6 m at year-end) with no debt; management expects runway of ≥12 months. Total assets fell to $103.3 m, liabilities to $20.3 m and equity to $83.0 m. Contingent consideration stands at $10.8 m and the liability from royalty-sale to OMERS declined to $3.9 m.
Key catalysts include Phase 2 data from imdusiran combinations, ongoing Phase 1a/1b dosing of oral PD-L1 inhibitor AB-101, and patent litigation milestones against Moderna and Pfizer/BioNTech (trial in Mar-26). Cost-control measures and regained global rights position Arbutus for partnering, but termination of Qilu removes future milestone streams.